Hyaluronic acid as treatment in children with bacterial acute rhinopharyngitis

Inhaled hyaluronic acid as ancillary treatment in children with bacterial acute rhinopharyngitis.

Article specifications

This clinical Trial was published in 2014 in Journal of biological regulators and homeostatic agents (IF 2015:1.469) by Italian specialists. The purpose of this study was to evaluate the effects of ancillary HA treatment in children with bacterial ARP. Globally, 51 children (27 males, mean age 5.9 ± 2.1 years) with bacterial ARP were enrolled in the study. At baseline, children were randomly assigned to the treatment with: 125 mg of thiamphenicol diluted in 4 mL of saline isotonic solution twice daily (group A) or with 125 mg of thiamphenicol plus 4 ml of sodium hyaluronate 0.2% plus xylitol 5% (Aluneb, Sakura Italia) twice daily (group B) administered by the nasal device Rinowash (Airliquide Medical System, Italy) and connected to an aerosol nebulizer with pneumatic compressor (1.5 bar per 5 L/min) Nebula (Airliquide Medical System, Italy), for 10 days. VAS, nasopharyngeal spotting, neutrophils and bacteria were assessed at baseline and after the treatment.

 

Results

Both treatments induced significant reduction of symptom perception, spotting, neutrophil and bacteria count. However, thiamphenicol plus HA was able to significantly induce a greater effect on sVAS, neutrophil count, and bacteria count than thiamphenicol alone. In conclusion, this study provides the first evidence that intranasal HA, as ancillary treatment, may be able to improve topical antibiotic efficacy in children with bacterial ARP.